Basic Information
| LncRNA/CircRNA Name | lncRNA-SARCC |
| Synonyms | P2RY1 |
| Region | GRCh38_3:152834693-152841439 |
| Ensemble | ENSG00000169860 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | renal cell carcinoma |
| ICD-0-3 | C64.9 |
| Methods | Luciferase assay, qPCR |
| Sample | The human renal cell carcinoma cell lines (SW839, OSRC-2, A498, 769-P, 786-O), renal cancer tissues. |
| Expression Pattern | down-regulated |
| Function Description | Here, we identified LncRNA-ENST00000460407 and concluded that it functioned as a tumor suppressor as well as a potential diagnostic or prognostic marker in RCC. This LncRNA could directly bind to AR and post-transcriptionally suppress AR protein and transactivation to regulate signals such as miR-143-3p/AKT/MMP-13/K-RAS/P-ERK to influence RCC cell invasion, migration and proliferation.Significantly, we find that Sunitinib induces LncRNASARCC expression, and the level of LncRNA-SARCC determines the sensitivity to this drug.The vast majority of patients with mRCC have only a median of 13 months survival time. |
| Pubmed ID | 28644440 |
| Year | 2017 |
| Title | LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. |
External Links
| Links for lncRNA-SARCC | GenBank HGNC NONCODE |
| Links for renal cell carcinoma | OMIM COSMIC |